InflaRx (IFRX)
(Delayed Data from NSDQ)
$0.80 USD
-0.01 (-1.83%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.80 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IFRX 0.80 -0.01(-1.83%)
Will IFRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IFRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IFRX
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
IFRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
Other News for IFRX
InflaRx reports Q2 EPS (21c) vs. (24c) last year
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update | IFRX Stock News
InflaRx reports Q2 results
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 | IFRX Stock News
InflaRx (IFRX) Faces Nasdaq Listing Challenge Due to Low Share Price | IFRX Stock News